Washburn Capital Management Inc. Purchases New Stake in Eli Lilly and Company (NYSE:LLY)

Washburn Capital Management Inc. purchased a new stake in shares of Eli Lilly and Company (NYSE:LLYGet Rating) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,898 shares of the company’s stock, valued at approximately $615,000.

Several other large investors have also recently bought and sold shares of the business. Cordant Inc. acquired a new position in Eli Lilly and in the 1st quarter worth about $25,000. HWG Holdings LP acquired a new position in Eli Lilly and in the 4th quarter worth about $28,000. Icapital Wealth LLC acquired a new position in Eli Lilly and in the 1st quarter worth about $28,000. Selective Wealth Management Inc. acquired a new position in Eli Lilly and in the 1st quarter worth about $33,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new position in Eli Lilly and in the 1st quarter worth about $33,000. 82.45% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and

In related news, Director Jackson P. Tai bought 656 shares of the company’s stock in a transaction dated Friday, August 12th. The stock was acquired at an average cost of $304.19 per share, with a total value of $199,548.64. Following the acquisition, the director now owns 62,857 shares in the company, valued at approximately $19,120,470.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Eli Lilly and news, Director Jackson P. Tai purchased 656 shares of the company’s stock in a transaction that occurred on Friday, August 12th. The stock was purchased at an average cost of $304.19 per share, with a total value of $199,548.64. Following the acquisition, the director now directly owns 62,857 shares of the company’s stock, valued at approximately $19,120,470.83. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 177,243 shares of the firm’s stock in a transaction on Wednesday, July 6th. The shares were sold at an average price of $330.28, for a total value of $58,539,818.04. Following the sale, the insider now directly owns 103,983,810 shares of the company’s stock, valued at $34,343,772,766.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 328,125 shares of company stock valued at $108,581,151. Corporate insiders own 0.12% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on LLY. Morgan Stanley upped their target price on Eli Lilly and from $395.00 to $412.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 7th. JPMorgan Chase & Co. upped their price target on Eli Lilly and from $340.00 to $355.00 in a research note on Wednesday, June 1st. StockNews.com upgraded Eli Lilly and from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 14th. Citigroup upped their price target on Eli Lilly and from $285.00 to $370.00 in a research note on Thursday, August 25th. Finally, Barclays upped their price target on Eli Lilly and from $333.00 to $355.00 and gave the stock an “overweight” rating in a research note on Thursday, July 7th. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $332.19.

Eli Lilly and Stock Performance

Eli Lilly and stock traded up $0.21 during trading hours on Friday, hitting $311.08. The stock had a trading volume of 101,703 shares, compared to its average volume of 2,237,822. The company has a 50-day moving average of $314.33 and a two-hundred day moving average of $304.45. The company has a quick ratio of 0.85, a current ratio of 1.10 and a debt-to-equity ratio of 1.70. The company has a market cap of $295.58 billion, a PE ratio of 49.58, a price-to-earnings-growth ratio of 1.92 and a beta of 0.38. Eli Lilly and Company has a fifty-two week low of $220.20 and a fifty-two week high of $335.33.

Eli Lilly and (NYSE:LLYGet Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.86 by ($0.61). The firm had revenue of $6.49 billion during the quarter, compared to analyst estimates of $6.85 billion. Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The company’s revenue was down 3.7% on a year-over-year basis. During the same period last year, the company earned $1.87 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 7.97 EPS for the current fiscal year.

Eli Lilly and Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 9th. Stockholders of record on Monday, August 15th were issued a $0.98 dividend. The ex-dividend date of this dividend was Friday, August 12th. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.26%. Eli Lilly and’s payout ratio is presently 62.52%.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.